Previous studies revealed that 6.4% of NRF2 MTs occur in HCC patients, and constitutive activation of NRF2 occurs more frequently in HCC cases [13,32,37,39,40,41]. This evidence concerns the gene NFE2L2 and hepatocellular carcinoma.